Shots:
- The data includes P-l/lla study involves assessing BI-1206 + rituximab in patients with FL, MZL and MCL who have r/r to rituximab. The study demonstrated at BI-1206 is generating the first signs of clinical response in patients
- The company also presents results from two preclinical studies. The preclinical data further reinforce the efficacy and tolerability profile of BI-1206
- BI-1206 has a novel mode-of-action, acts by blocking the single inhibitory Ab checkpoint receptor FcγRIIB to unlock anti-cancer immunity in both liquid and solid tumors. The therapy is currently being evaluated in P-I/II study in combination with Keytruda & in P-I/IIa study in combination with MabThera (rituximab) for NHL
Click here to read the full press release/ article | Ref: PRNewswire | Image: Contract Pharma
The post BioInvent Presents New Clinical and Preclinical Data of BI-1206 at ASH Annual Meeting first appeared on PharmaShots.
